Veryan was originally formed in 2003 as the result of a technology spin out from Imperial College, London, UK, and has designed, patented and developed a highly innovative three dimensional (3D) Nitinol (nickel-titanium alloy) stent technology – BioMimics 3D – based on the pioneering work by Professor Colin Caro (Emeritus Professor of Physiological Mechanics, Dept. of Bioengineering, Imperial College London) on the link between vessel geometry, blood flow mechanics and vascular disease.1
In December 2018, Veryan was acquired by Otsuka Medical Devices Co. Ltd., a 100% subsidiary of Otsuka Holdings Co., Ltd. Veryan’s BioMimics 3D® peripheral vascular stent received U.S. FDA approval on 4 October, 2018. Following the acquisition, Veryan and Otsuka Medical Devices have plans to collaborate in developing Swirling Flow® stents for use in the treatment of vascular disease.
Veryan’s head office is in Horsham, West Sussex, UK, and the research and development facility is in Galway, Ireland.
Veryan’s Quality Management System is certified in compliance with I.S. EN ISO 13485:2016 (click here to view)
1. Caro, C. G. Discovery of the role of wall shear in atherosclerosis. Arterioscler Thromb Vasc Biol 29, 158–61 (2009).